Corvus Pharmaceuticals (CRVS) Free Cash Flow (2015 - 2026)

Corvus Pharmaceuticals' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$10.5 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 26.1% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$35.1 million (down 23.0% YoY), while the FY2025 annual figure was -$33.0 million, down 29.68% from the prior year.
• Free Cash Flow was -$10.5 million for Q1 2026 at Corvus Pharmaceuticals, down from -$9.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$5.2 million in Q1 2024 to a low of -$10.5 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$7.1 million across 5 years, with a median of -$6.4 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 51.59% in 2022, then sank 63.83% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$7.5 million in 2022, then surged by 31.54% to -$5.2 million in 2023, then plunged by 63.83% to -$8.5 million in 2024, then slipped by 8.87% to -$9.2 million in 2025, then fell by 13.55% to -$10.5 million in 2026.
• The last three Free Cash Flow figures came in at -$10.5 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.6 million (Q3 2025), per Business Quant data.